Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United StatesIPO:
05 March 2021Website:
http://www.scilexholding.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:58:47 GMTDividend
Analysts recommendations
Institutional Ownership
SCLX Latest News
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its Chief Executive Officer and President, Jaisim Shah, and Executive Chairman, Henry Ji, Ph.D., will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York, at 4:00 p.m. Eastern Time on Friday, July 5, 2024. The ceremony will be held in celebration of Scilex's launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for the prophylactic treatment of painful gout flares.
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a commitment letter (the “Commitment Letter”) with Perigrove LLC and Graf Holdings (collectively the “Lender”) for a $100 million 5-year term financing with royalty-based payments (“Commitment”). The Company intends to use the funds to repay the outstanding amount of its existing senior secured loan provided by Oramed Pharmaceuticals Inc., which is approximately $85 million. The Company intends to use the rest of the funds raised, which is estimated to be $15 million, for general corporate purposes.
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S. GLOPERBA ® , an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is launching today.
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has the FDA approval of commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June 2024. Scilex will stock Gloperba® in all major wholesalers and pharmacies starting June 10, 2024.
PALO ALTO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to both the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority regarding illegal market manipulation of the common stock of Scilex.
Has the potential to Enhance the visibility of Scilex's Non-Opioid Pain Management Therapeutics In Global Financial Markets Has the potential to Enhance the visibility of Scilex's Non-Opioid Pain Management Therapeutics In Global Financial Markets
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to the U.S. House of Representatives on illegal market manipulation of the common stock of Scilex.
Last week, the company said it is hiring a firm to look into manipulation of its stock. The company just got approval in February from the FDA for acute migraine treatment Elyxyb.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it will be presenting data on ELYXYB™ (celecoxib oral solution) for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society (AHS) to be held on June 14-18, 2023 in Austin, Texas.
What type of business is Scilex Holding?
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
What sector is Scilex Holding in?
Scilex Holding is in the Healthcare sector
What industry is Scilex Holding in?
Scilex Holding is in the Drug Manufacturers - General industry
What country is Scilex Holding from?
Scilex Holding is headquartered in United States
When did Scilex Holding go public?
Scilex Holding initial public offering (IPO) was on 05 March 2021
What is Scilex Holding website?
https://www.scilexholding.com
Is Scilex Holding in the S&P 500?
No, Scilex Holding is not included in the S&P 500 index
Is Scilex Holding in the NASDAQ 100?
No, Scilex Holding is not included in the NASDAQ 100 index
Is Scilex Holding in the Dow Jones?
No, Scilex Holding is not included in the Dow Jones index
When does Scilex Holding report earnings?
The next expected earnings date for Scilex Holding is 09 August 2024